GLAXOSMITHKLINE AND CHEMOCENTRYX, INC. ENTER INTO $1.5 BILLION DRUG DISCOVERY AND DEVELOPMENT ALLIANCE IN INFLAMMATORY DISORDERS

GlaxoSmithKline (GSK) and ChemoCentryx, Inc. announced a worldwide multi-target strategic alliance to discover, develop and market novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory disorders, including Traficet-EN in late stage development for the treatment of inflammatory bowel disease (IBD). This collaboration provides GSK access to selected targets from one of the broadest pipelines of chemokine-based therapeutics in the biopharmaceutical industry leveraging ChemoCentryx's expertise and pioneering insight into the chemokine system.
BioSpace